Novel iridium (III)-derived organometallic compound for the inhibition of human platelet activation

Mostrar otras versiones (1)

Since cisplatin achieved clinical success, transition metal platinum (Pt) drugs have been effectively used for the treatment of cancer. Iridium (Ir) compounds are considered to be potential alternatives to Pt compounds, as they possess promising anticancer effects with minor side effects. Platelet a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shyu, Kou-Gi, Velusamy, Marappan, Hsia, Chih-Wei, Yang, Chih-Hao, Hsia, Chih-Hsuan, Chou, Duen-suey, Jayakumar, Thanasekaran, Sheu, Joen-Rong, Li, Jiun-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846649/
https://www.ncbi.nlm.nih.gov/pubmed/29436605
http://dx.doi.org/10.3892/ijmm.2018.3472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846649/
https://www.ncbi.nlm.nih.gov/pubmed/29436605
http://dx.doi.org/10.3892/ijmm.2018.3472

Ejemplares similares